Evidence map›Paper›PMID 39959585›Full record

ArticleFrontiers in immunology2024

Case report: JAK inhibitor treatment of immune dysregulation symptoms in a patient with PTPN2 deficiency.

Anna Roppelt, Ulyana Markina, Irina Beloglazova, Vasily Parshin, Dmitry Kanner, Dmitry Pershin, Mariia Fadeeva, Elena Raykina, Maxim Aleksenko, Alexander Karaulov and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anna RoppeltMoscow Research and Practical Center of Allergy and Immunology, Clinical City Hospital 52, Department of Health of the City of Moscow, Moscow, Russia.
Ulyana MarkinaMoscow Research and Practical Center of Allergy and Immunology, Clinical City Hospital 52, Department of Health of the City of Moscow, Moscow, Russia.
Irina BeloglazovaMoscow Research and Practical Center of Allergy and Immunology, Clinical City Hospital 52, Department of Health of the City of Moscow, Moscow, Russia.
Vasily ParshinMoscow Research and Practical Center of Allergy and Immunology, Clinical City Hospital 52, Department of Health of the City of Moscow, Moscow, Russia.
Dmitry KannerMoscow Oncology Hospital 62, Department of Health of the City of Moscow, Moscow, Russia.
Dmitry PershinLaboratory of Hematopoietic Stem Cell Transplantation and Immunotherapy and Laboratory of Molecular Biology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Mariia FadeevaLaboratory of Hematopoietic Stem Cell Transplantation and Immunotherapy and Laboratory of Molecular Biology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Elena RaykinaLaboratory of Hematopoietic Stem Cell Transplantation and Immunotherapy and Laboratory of Molecular Biology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Maxim AleksenkoLaboratory of Hematopoietic Stem Cell Transplantation and Immunotherapy and Laboratory of Molecular Biology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Alexander KaraulovDepartment of Clinical Immunology and Allergy, First Sechenov Moscow State Medical University (Sechenov University), Moscow, Russia.
Mariana LysenkoMoscow Research and Practical Center of Allergy and Immunology, Clinical City Hospital 52, Department of Health of the City of Moscow, Moscow, Russia.
Daria FominaMoscow Research and Practical Center of Allergy and Immunology, Clinical City Hospital 52, Department of Health of the City of Moscow, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A heterozygous mutation in the

Indexed as

Janus Kinase InhibitorsProtein Tyrosine Phosphatase, Non-Receptor Type 2PyrazolesAdultHumansLung Diseases, InterstitialMaleNitrilesPyrimidinesTreatment OutcomeJanus Kinase InhibitorsNitrilesProtein Tyrosine Phosphatase, Non-Receptor Type 2PTPN2 protein, humanPyrazolesPyrimidinesruxolitinibcase reportimmune dysregulationinborn errors of immunityJAK-inhibitorPTPN2

Identifiers

PMID39959585
PMCPMC11825476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.